The presentation by Alberto Zambon about statin/ezetimibe combinations starts with evidence on efficacy of LDL-lowering therapies down to below 1.4 mmol/L (IMPROVE_IT trial). Data suggest that:

• Every 39 mg/dl reduction in LDL-C reduces annual CV risk by up to 28%, regardless of mechanism.
• Ezetimibe-statin combination therapy was associated with greater cardiovascular benefits in patients with diabetes than in those without diabetes.
• The benefit of ezetimibe is consistent in ACS patients with and without polyvascular disease and type 2 DM.

After some evidence from the Jupier TRIAL about sub-optimal cholesterol response to statin therapy and the future risk of cardiovascular disease, the presentation ends with the emerging concepts of individualized cholesterol-lowering therapy.